Journal article

MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance

Y Sheng, CP Ng, R Lourie, ET Shah, Y He, KY Wong, I Seim, I Oancea, C Morais, PL Jeffery, J Hooper, GC Gobe, MA McGuckin

International Journal of Cancer | WILEY | Published : 2017

Abstract

Metastatic renal cell carcinoma is a largely incurable disease, and existing treatments targeting angiogenesis and tyrosine kinase receptors are only partially effective. Here we reveal that MUC13, a cell surface mucin glycoprotein, is aberrantly expressed by most renal cell carcinomas, with increasing expression positively correlating with tumor grade. Importantly, we demonstrated that high MUC13 expression was a statistically significant independent predictor of poor survival in two independent cohorts, particularly in stage 1 cancers. In cultured renal cell carcinoma cells MUC13 promoted proliferation and induced the cell cycle regulator, cyclin D1, and inhibited apoptosis by inducing the..

View full abstract

University of Melbourne Researchers

Grants

Awarded by NHMRC


Awarded by National Health and Medical Research Council of Australia


Funding Acknowledgements

Grant sponsor: This work was supported by NHMRC project grant 1060698 and by funding from the Mater Foundation, MAM is supported by a NHMRC Senior Research Fellowship. RL was partly supported by a Betty McGrath/Mater Practitioner Research Fellowship. IS is supported by a QUT Vice-Chancellor's Senior Research Fellowship. The Translational Research Institute (TRI) is supported by a grant from the Australian Government.